Allergy Therapeutics (OTCMKTS:AGYTF) & Jaguar Animal Health (NASDAQ:JAGX) Critical Comparison

Jaguar Animal Health (NASDAQ:JAGX) and Allergy Therapeutics (OTCMKTS:AGYTF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Volatility and Risk

Jaguar Animal Health has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Profitability

This table compares Jaguar Animal Health and Allergy Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-169.04%	N/A	-115.55%
Allergy Therapeutics	N/A	N/A	N/A

Insider & Institutional Ownership

12.0% of Jaguar Animal Health shares are owned by institutional investors. 2.0% of Jaguar Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Jaguar Animal Health and Allergy Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1	0	0	0	1.00
Allergy Therapeutics	0	0	0	0	0.00

Earnings and Valuation

This table compares Jaguar Animal Health and Allergy Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51 million	0.07	-$53.43 million	($591.92)	-0.00
Allergy Therapeutics	$71.22 million	1.45	-$51.94 million	N/A	N/A

Allergy Therapeutics has higher revenue and earnings than Jaguar Animal Health.

Summary

Allergy Therapeutics beats Jaguar Animal Health on 6 of the 9 factors compared between the two stocks.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.